,17 years,Where, in the opinion of a qualified health professional, the donor has sufficient knowledge and understanding of what is involved in the process of blood donation to give their informed consent, or otherwise with the written consent of a person with parental responsibility.,
 ,First time donors over 60 years,— at the discretion of the doctor in the blood establishment,
 ,Over 65 years,— with permission of the doctor in the blood establishment, given annually,
Body weight,≥ 50 kg for donors either of whole blood or apheresis blood components,
Haemoglobin,For females ≥ 125 g/l,For males ≥ 135 g/l,Applicable to allogeneic donors of whole blood and cellular components,
Protein,≥ 60 g/l,The protein analysis for apheresis plasma donations must be performed at least annually,
Platelets,Platelet number greater than or equal to 150 x 10 9 /1,Level required for apheresis platelet donors,
Cardiovascular disease,Prospective donors with active or past serious cardiovascular disease, except congenital abnormalities with complete cure,
Central nervous system disease,A history of serious CNS disease,
Abnormal bleeding tendency,Prospective donors who give a history of a coagulopathy,
Repeated episodes of syncope, or a history of convulsions,Other than childhood convulsions or where at least three years have elapsed since the date the donor last took anticonvulsant medication without any recurrence of convulsions,
Gastrointestinal. Genitourinary, haematological, immunological, metabolic, renal, or respiratory system diseases,Prospective donors with serious active, chronic, or relapsing disease,
Diabetes,If being treated with insulin,
Infectious diseases,Hepatitis B, except for HBsAg-negative persons who are demonstrated to be immune,
 ,Hepatitis C,
 ,HIV – 1 and 2,
 ,HTLV I/II,
 ,Babesiosis (*),
 ,Kala Azar (visceral leishmaniasis) (*),
 ,Trypanosomiasis cruzi (Chagas' disease) (*),
Malignant diseases,Except in situ cancer with complete recovery,
Transmissible spongiform encephalopathies (TSEs) (e.g. Creutzfeldt Jakob Disease, variant Creutzfeldt Jakob Disease),Persons who have a family history which places them at risk of developing a TSE, or persons who have received a corneal or dura mater graft, or who have been treated in the past with medicines made from human pituitary glands. For variant Creutzfeldt Jacob disease, further precautionary measures may be recommended.,
Intravenous (IV) or intramuscular (IM) drug use,Any history of non-prescribed IV or IM drug use, including body-building steroids or hormones,
Xenotransplant recipients, ,
Sexual behaviour,Persons whose sexual behaviour puts them at high risk of acquiring severe infectious diseases that can be transmitted by blood,
Brucellosis (*),2 years following the date of full recovery,
Osteomyelitis,2 years after confirmed cured,
Q fever (*),2 years following the date of confirmed cure,
Syphilis (*),1 year following the date of confirmed cure,
Toxoplasmosis (*),6 months following the date of clinical recovery,
Tuberculosis,2 years following the date of confirmed cure,
Rheumatic fever,2 years following the date of cessation of symptoms, unless evidence of chronic heart disease,
Fever >38°C,2 weeks following the date of cessation of symptoms,
Flu-like illness,2 weeks after cessation of symptoms,
Malaria (*), ,
— individuals who have lived in a malarial area within the first five years of life,3 years following return from last visit to any endemic area, provided person remains symptom free; may be reduced to 4 months if an immunologic or molecular genomic test is negative at each donation.,
— individuals with a history of malaria,3 years following cessation of treatment and absence of symptoms. Donations may be accepted thereafter only if an immunologic or molecular genomic test is negative,
— asymptomic visitors to endemic areas,6 months after leaving the endemic area unless an immunologic or molecular genomic test is negative,
— individuals with a history of undiagnosed febrile illness during or within six months of a visit to an endemic area,3 years following resolution of symptoms; may be reduced to 4 months if an immunologic or molecular test is negative,
 West Nile Virus (WNV) (*),28 days after leaving a risk area of locally acquired West Nile Virus unless an individual Nucleic Acid Test (NAT) is negative,
— Endoscopic examination using flexible instruments, — mocusal splash with blood or needlestick injury, — transfusion of blood components, — tissue or cell transplant of human origin, — major surgery, — tattoo or body piercing, — acupuncture unless performed by a qualified practitioner and with sterile single-use needles, — persons at risk due to close household contact with persons with hepatitis B.,Defer 6 months, or 4 months provided a NAT test for hepatitis C is negative,
Persons whose behaviour or activity places them at risk of acquiring infectious diseases that may be transmitted by blood.,Defer after cessation of risk behaviour for a period determined by the disease in question, and by the availability of appropriate tests.,
Attenuated viruses or bacteria,4 weeks,
Inactivated/killed viruses, bacteria or rickettsiae,No deferral if well,
Toxoids,No deferral if well,
Hepatitis A or hepatitis B vaccines,No deferral if well and if no exposure,
Rabies,No deferral if well and if no exposure If vaccination is given following exposure defer for one year,
Tick-borne encephalitis vaccines,No deferral if well and if no exposure,
Pregnancy,6 months after delivery or termination, except in exceptional circumstances and at the discretion of a physician,
Minor surgery,1 week,
Dental treatment,Minor treatment by dentist or dental hygienist – defer until next day (NB: Tooth extraction, root-filling and similar treatment is considered as minor surgery),
Medication,Based on the nature of the prescribed medicine, its mode of action an the disease being treated,
Particular epidemiological situations (e.g. disease outbreaks),Deferral consistent with the epidemiological situation,
Serious cardiac disease,Depending on the clinical setting of the blood collection,
Active bacterial infection, ,

Red cell preparations and whole blood (if used for transfusion as whole blood),+2 to +6°C,28 to 49 days according to the processes used for collection, processing and storage,
Platelet preparations,+20 to +24°C,5 days, may be stored for 7 days in conjunction with detection or reduction of bacterial contamination,
Granulocytes,+20 to +24°C,24 hours,

Red blood cells,Up to 30 years according to processes used for collection, processing and storage,
Platelets,Up to 24 months according to processes used for collection, processing and storage,
Plasma and cryoprecipitate,Up to 36 months according to processes used for collection, processing and storage,
Cryopreserved red blood cells and platelets must be formulated in a suitable medium after thawing. The allowable storage period after thawing to depend on the method used.,
1. Red cell preparations,The components listed in points 1.1 to 1.8 may be further processed within blood establishments and must be labelled accordingly,
1.1,Red cells,
1.2,Red cells, buffy coat removed,
1.3,Red cells, leucocyte-depleted,
1.4,Red cells, in additive solution,
1.5,Red cells, buffy coat removed, in additive solution,
1.6,Red cells, leucocyte-depleted, in additive solution,
1.7,Red cells, apheresis,
1.8,Whole blood,
2. Platelet preparations,The components listed in points 2.1 to 2.6 may be further processed within blood establishments and must be labelled accordingly,
2.1,Platelets, apheresis,
2.2,Platelets, apheresis, leucocyte-depleted,
2.3,Platelets, recovered, pooled,
2.4,Platelets, recovered, pooled, leucocyte-depleted,
2.5,Platelets, recovered, single unit,
2.6,Platelets, recovered, single unit, leucocyte-depleted,
3. Plasma preparations,The components listed in 3.1 to 3.3 may be further processed within blood establishments and must be labelled accordingly,
3.1,Fresh-frozen plasma,
3.2,Fresh-frozen plasma, cryoprecipitate-depleted,
3.3,Cryoprecipitate,
4.,Granulocytes, apheresis,


Red cells,Volume,Valid for storage characteristics to maintain product within specifications for haemoglobin and haemolysis,
 ,Haemoglobin (*),Not less than 45g per unit,
 ,Haemolysis,Less than 0.8% of red cell mass at end of the shelf life,
Red cells, buffy coat removed,Volume,Valid for storage characteristics to maintain product within specifications for haemoglobin and haemolysis,
 ,Haemoglobin (*),Not less than 43 g per unit,
 ,Haemolysis,Less than 0.8% of red cell mass at the end of the shelf life,
Red cells, leucocyte-depleted,Volume,Valid for storage characteristics to maintain product within specifications for haemoglobin and haemolysis,
 ,Haemoglobin (*),Not less than 40g per unit,
 ,Leucocyte content,Less than 1 x 10 6 per unit,
 ,Haemolysis,Less than 0.8% of red cell mass at the end of the shelf life,
Red cells, in additive solution,Volume,Valid for storage characteristics to maintain product within specifications for haemoglobin and haemolysis,
 ,Haemoglobin (*),Not less than 45g per unit,
 ,Haemolysis,Less than 0.8% of red cell mass at end of the shelf life,
Red cells, buffy coat removed, in additive solution,Volume,Valid for storage characteristics to maintain product within specifications for haemoglobin and haemolysis,
 ,Haemoglobin (*),Not less than 43g per unit,
 ,Haemolysis,Less than 0.8% of red cell mass at the end of the shelf life,
Red cells, leucocyte-depleted, in additive solution,Volume,Valid for storage characteristics to maintain product within specifications for haemoglobin and haemolysis,
 ,Haemoglobin (*),Not less than 40g per unit,
 ,Leucocyte content,Less than 1 x 10 6 per unit,
 ,Haemolysis,Less than 0.8% of red cell mass at the end of the shelf life,
Red cells, apheresis,Volume,Valid for storage characteristics to maintain product within specifications for haemoglobin and haemolysis,
 ,Haemoglobin (*),Not less than 40g per unit,
 ,Haemolysis,Less than 0.8% of red cell mass at the end of the shelf life,
Whole blood,Volume,Valid for storage characteristics to maintain product within specifications for haemoglobin and haemolysis 450ml +/- 50ml For paediatric autologous whole blood collections – not to exceed 10.5ml per kg body weight,
 ,Haemoglobin (*),Not less than 45g per unit,
 ,Haemolysis,Less than 0.8% of red cell mass at the end of the shelf life,
Platelets, apheresis,Volume,Valid for storage characteristics to maintain product within specifications for pH,
 ,Platelet content,Variations in platelet content per single donation are permitted within the limits that comply with validated preparation and preservation conditions,
 ,pH, Minimum 6.4 corrected for 22°C, at the end of the shelf life ,
Platelets, apheresis, leucocyte-depleted,Volume,Valid for storage characteristics to maintain product within specifications for pH,
 ,Platelet content,Variations in platelet content per single donation are permitted within the limits that comply with validated preparation and preservation conditions,
 ,Leucocyte content,Less than 1 x 10 6 per unit,
 ,pH, Minimum 6.4 corrected for 22°C, at the end of the shelf life ,
Platelets, recovered, pooled,Volume,Valid for storage characteristics to maintain product within specifications for pH,
 ,Platelet content,Variations in platelet content per pool are permitted within limits that comply with validated preparation and preservation conditions,
 ,Leucocyte content,Less than 0.2 x 10 9 per single unit (platelet-rich plasma method) Less than 0.05 x 10 9 per single unit (buffy coat method),
 ,pH, Minimum 6.4 corrected for 22°C, at the end of the shelf life ,
Platelets, recovered, pooled, leucocyte-depleted,Volume,Valid for storage characteristics to maintain product within specifications for pH,
 ,Platelet content,Variations in platelet content per pool are permitted within limits that comply with validated preparation and preservation conditions,
 ,Leucocyte content,Less than 1 x 10 6 per pool,
 ,pH, Minimum 6.4 corrected for 22°C, at the end of the shelf life ,
Platelets, recovered, single unit,Volume,Valid for storage characteristics to maintain product within specifications for pH,
 ,Platelet content,Variations in platelet content per single unit are permitted within limits that comply with validated preparation and preservation conditions,
 ,Leucocyte content,Less than 0.2 x 10 9 per single unit (platelet-rich plasma method) Less than 0.05 x 10 9 per single unit (buffy coat method),
 ,pH, Minimum 6.4 corrected for 22°C, at the end of the shelf life ,
Platelets, recovered, single unit, leucocyte-depleted,Volume,Valid for storage characteristics to maintain product within specifications for pH,
 ,Platelet content,Variations in platelet content per single unit are permitted within limits that comply with validated preparation and preservation conditions,
 ,Leucocyte content,Less than 1 x 10 6 per unit,
 ,pH, Minimum 6.4 corrected for 22°C, at the end of the shelf life ,
Plasma, fresh-frozen,Volume,Stated volume +/- 10%,
 ,Factor VIIIc(*),Average (after freezing and thawing): 70% or more of the value of the freshly collected plasma unit,
 ,Total protein,Not less than 50g/l,
 ,Residual cellular content(*),Red cells: less than 6.0 x 10 9 /l Leucocytes: less than 0.1 x 10 9 /l Platelets: less than 50 x 10 9 /l,
Plasma, fresh-frozen, cryoprecipitate-depleted,Volume,Stated volume +/-10%,
 ,Residual cellular content(*),Red cells: less than 6.0 x 10 9 /l Leucocytes: less than 0.1 x 10 9 /l Platelets: less than 50 x 10 9 /l,
Cryoprecipitate,Fribrinogen content(*),Greater than or equal to 140mg per unit,
 ,Fractor VIIIc content (*),Greater than or equal to 70 international units per unit,
Granulocytes, apheresis,Volume,Less than 500ml,
 ,Granulocyte content,Greater than 1 x 10 10 granulocytes per unit,